A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

Autor: Tait DL; Carolinas Medical Center, Blumenthal Cancer Center, Charlotte, NC 28203, USA. david.tait@carolinashealthcare.org, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2011 Apr; Vol. 121 (1), pp. 118-21. Date of Electronic Publication: 2010 Dec 14.
DOI: 10.1016/j.ygyno.2010.11.027
Abstrakt: Objective: The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial carcinoma.
Methods: Patients with advanced or recurrent carcinoma of the endometrium previously treated with one chemotherapy regimen were treated on a phase II trial conducted by the Gynecologic Oncology Group (GOG). Gemcitabine was administered as an intravenous infusion at a dose of 800 mg/m² over 30 min on days 1 and 8 every 21 days.
Results: Twenty-four patients were entered by 11 GOG member institutions. One patient was ineligible due to wrong primary tumor. A total of ninety 21-day cycles of therapy were administered with 35% of patients receiving four or more cycles. All patients had been previously treated with a platinum-based regimen. One patient had a partial response (4%), nine had stable disease (39%), and twelve had increasing disease (52%). The median progression-free survival was 1.7 months. Treatment was generally well tolerated with only 22% of patients experiencing grade 3 or grade 4 hematologic toxicity. There was one treated-related death due to pulmonary toxicity.
Conclusion: Gemcitabine has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.
(Copyright © 2010 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: